MA54318A - Formulations de capsules - Google Patents

Formulations de capsules

Info

Publication number
MA54318A
MA54318A MA054318A MA54318A MA54318A MA 54318 A MA54318 A MA 54318A MA 054318 A MA054318 A MA 054318A MA 54318 A MA54318 A MA 54318A MA 54318 A MA54318 A MA 54318A
Authority
MA
Morocco
Prior art keywords
capsule formulations
capsule
formulations
Prior art date
Application number
MA054318A
Other languages
English (en)
Other versions
MA54318B1 (fr
Inventor
Manmohan Reddy Leleti
Jay P Powers
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70849818&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA54318(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MA54318A publication Critical patent/MA54318A/fr
Publication of MA54318B1 publication Critical patent/MA54318B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA54318A 2018-11-30 2019-11-27 Formulations de capsules MA54318B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862773848P 2018-11-30 2018-11-30
PCT/US2019/063547 WO2020112961A1 (fr) 2018-11-30 2019-11-27 Formulations de capsules

Publications (2)

Publication Number Publication Date
MA54318A true MA54318A (fr) 2021-10-06
MA54318B1 MA54318B1 (fr) 2023-08-31

Family

ID=70849818

Family Applications (2)

Application Number Title Priority Date Filing Date
MA54318A MA54318B1 (fr) 2018-11-30 2019-11-27 Formulations de capsules
MA62992A MA62992B1 (fr) 2018-11-30 2019-11-27 Formulations de capsules

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA62992A MA62992B1 (fr) 2018-11-30 2019-11-27 Formulations de capsules

Country Status (31)

Country Link
US (4) US20200170957A1 (fr)
EP (3) EP4487915A3 (fr)
JP (1) JP7342124B2 (fr)
KR (1) KR102586747B1 (fr)
CN (1) CN113164403A (fr)
AR (1) AR117219A1 (fr)
AU (1) AU2019389031B2 (fr)
BR (1) BR112021010285A2 (fr)
CA (1) CA3120999C (fr)
CL (1) CL2021001389A1 (fr)
CY (1) CY1126079T1 (fr)
DK (2) DK4233850T3 (fr)
ES (2) ES2998858T3 (fr)
FI (2) FI3886820T3 (fr)
HR (2) HRP20241735T1 (fr)
HU (2) HUE069633T2 (fr)
IL (1) IL283450B2 (fr)
LT (2) LT4233850T (fr)
MA (2) MA54318B1 (fr)
MD (2) MD4233850T2 (fr)
MX (1) MX2021006242A (fr)
NZ (1) NZ776554A (fr)
PL (2) PL4233850T3 (fr)
PT (2) PT4233850T (fr)
RS (2) RS64250B1 (fr)
SG (1) SG11202105572UA (fr)
SI (2) SI4233850T1 (fr)
SM (2) SMT202300153T1 (fr)
TW (1) TWI827745B (fr)
WO (1) WO2020112961A1 (fr)
ZA (1) ZA202103820B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4487915A3 (fr) 2018-11-30 2025-03-19 ChemoCentryx, Inc. Formulations de capsules
MX2022005406A (es) 2019-11-08 2022-05-24 Chemocentryx Inc Forma amorfa de un receptor de componente c5a de complemento.
CN116529241A (zh) * 2020-10-28 2023-08-01 坎莫森特里克斯公司 治疗化脓性汗腺炎的方法
MX2023004801A (es) * 2020-10-28 2023-05-10 Chemocentryx Inc Metodos de tratamiento de hidradenitis supurativa.
AU2021410668A1 (en) * 2020-12-21 2023-07-06 Chemocentryx, Inc. Treatment of c3 glomerulopathy using a c5a inhibitor
WO2023225533A1 (fr) * 2022-05-19 2023-11-23 Dow Global Technologies Llc Utilisation de complexes interpolymères à base de peg pour une solubilisation améliorée de médicaments de classe ii bcs
WO2025203055A1 (fr) * 2024-03-26 2025-10-02 Council Of Scientific And Industrial Research Formulation de dihydrofolate encapsulée pour supplémentation alimentaire en tant que supplément nutraceutique efficace et son procédé de préparation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
KR20070084531A (ko) 2004-11-24 2007-08-24 머크 앤드 캄파니 인코포레이티드 치환된 아미드의 경구 투여용 액체 및 반고체 약제학적제형
DE102005053066A1 (de) 2005-11-04 2007-05-10 Basf Ag Verwendung von Copolymeren als Solubilisatoren für in Wasser schwerlöslichen Verbindungen
MX2009012834A (es) * 2007-05-29 2010-05-17 Intrexon Corp Ligandos quirales de diacilhidrazina para modular la expresion de genes exogenos por medio de un complejo receptor de ecdisona.
SMT202200074T1 (it) * 2008-12-22 2022-03-21 Chemocentryx Inc Antagonisti di c5ar
JP5717768B2 (ja) 2010-03-10 2015-05-13 アッヴィ・バハマズ・リミテッド 固体組成物
HRP20171176T1 (hr) 2010-06-24 2017-10-06 Chemocentryx, Inc. C5ar antagonisti
US9034858B2 (en) * 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9074470B2 (en) 2010-12-27 2015-07-07 Seven Generations Energy Ltd. Methods for drilling and stimulating subterranean formations for recovering hydrocarbon and natural gas resources
MX386859B (es) 2014-02-05 2025-03-19 Lek Pharmaceuticals Composiciones farmacéuticas sólidas de antagonistas de los receptores de andrógenos.
EP3682879B1 (fr) 2014-09-29 2022-08-03 ChemoCentryx, Inc. Procédés et intermédiaires pour la préparation d'antagonistes c5ar
MX2022006069A (es) 2016-01-14 2023-01-12 Chemocentryx Inc Metodo para tratar glomerulopatia c3.
WO2017176620A2 (fr) 2016-04-04 2017-10-12 Chemocentryx, Inc. Antagonistes de c5ar solubles
EP3978523A1 (fr) 2017-04-03 2022-04-06 InflaRx GmbH Traitement de maladies inflammatoires au moyen d'inhibiteurs de l'activité c5a
CA3077395A1 (fr) 2017-10-30 2019-05-09 Chemocentryx, Inc. Composes deuteres utilises comme immunomodulateurs
US20190134020A1 (en) 2017-10-31 2019-05-09 Chemocentryx, Inc. C5aR INHIBITOR REDUCTION OF URINARY sCD163
CA3102403A1 (fr) 2018-06-07 2019-12-12 Chemocentryx, Inc. Dosage et effet d'un antagoniste de c5a avec une vasculite associee aux anca
EP4487915A3 (fr) 2018-11-30 2025-03-19 ChemoCentryx, Inc. Formulations de capsules

Also Published As

Publication number Publication date
BR112021010285A2 (pt) 2021-08-17
RS64250B1 (sr) 2023-06-30
PL4233850T3 (pl) 2025-03-17
HUE062551T2 (hu) 2023-11-28
US20220233453A1 (en) 2022-07-28
US20250375385A1 (en) 2025-12-11
LT4233850T (lt) 2025-01-27
PL3886820T3 (pl) 2023-08-14
US20240299306A1 (en) 2024-09-12
CY1126079T1 (el) 2023-11-15
CA3120999C (fr) 2025-04-01
SI4233850T1 (sl) 2025-03-31
EP4233850A3 (fr) 2023-09-20
DK4233850T3 (da) 2025-01-02
ZA202103820B (en) 2026-03-25
AU2019389031B2 (en) 2023-06-15
WO2020112961A1 (fr) 2020-06-04
KR102586747B1 (ko) 2023-10-06
AR117219A1 (es) 2021-07-21
SI3886820T1 (sl) 2023-07-31
CA3120999A1 (fr) 2020-06-04
ES2943492T3 (es) 2023-06-13
TW202038952A (zh) 2020-11-01
AU2019389031A1 (en) 2021-06-17
RS66362B1 (sr) 2025-01-31
SG11202105572UA (en) 2021-06-29
EP4233850B1 (fr) 2024-10-02
US20200170957A1 (en) 2020-06-04
CN113164403A (zh) 2021-07-23
KR20210098489A (ko) 2021-08-10
EP4487915A2 (fr) 2025-01-08
PT3886820T (pt) 2023-05-24
EP3886820A1 (fr) 2021-10-06
EP3886820B1 (fr) 2023-04-12
JP2022510304A (ja) 2022-01-26
IL283450B2 (en) 2024-06-01
PT4233850T (pt) 2024-12-30
HRP20241735T1 (hr) 2025-02-28
JP7342124B2 (ja) 2023-09-11
ES2998858T3 (en) 2025-02-21
FI4233850T3 (fi) 2024-12-30
SMT202300153T1 (it) 2023-09-06
IL283450B1 (en) 2024-02-01
HUE069633T2 (hu) 2025-04-28
CL2021001389A1 (es) 2021-12-24
SMT202400521T1 (it) 2025-01-14
US11951214B2 (en) 2024-04-09
EP3886820A4 (fr) 2022-08-24
MA62992B1 (fr) 2025-01-31
NZ776554A (en) 2024-12-20
HRP20230551T1 (hr) 2023-08-18
EP3886820B8 (fr) 2023-05-17
EP4233850A2 (fr) 2023-08-30
IL283450A (en) 2021-07-29
DK3886820T3 (da) 2023-05-15
MA54318B1 (fr) 2023-08-31
MX2021006242A (es) 2021-09-10
FI3886820T3 (fi) 2023-05-25
TWI827745B (zh) 2024-01-01
LT3886820T (lt) 2023-06-12
MD4233850T2 (ro) 2025-02-28
EP4487915A3 (fr) 2025-03-19
MD3886820T2 (ro) 2023-07-31

Similar Documents

Publication Publication Date Title
EP3886820A4 (fr) Formulations de capsules
EP3603642A4 (fr) Préparation pharmaceutique
IL285674A (en) Pharmaceutical formulations
EP3454847A4 (fr) Formulations de médicaments améliorées
EP4340649A4 (fr) Capsule
HUE069648T2 (hu) Gyógyszerészeti készítmény
IL271908A (en) Over-compressed pharmaceutical preparations
PL3787596T3 (pl) Ulepszone formulacje farmaceutyczne
EP3706731A4 (fr) Formulations améliorées de médicaments
DK3996688T3 (da) Farmaceutisk præparat
EP3622941A4 (fr) Médicament emballé
EP3898451B1 (fr) Capsule de boisson
ZAA201801557S (en) Capsule
ZAA201801556S (en) Capsule
PH32018000897S1 (en) Capsule
ZAF201800730S (en) Capsule
UA34979S (uk) Капсула
GB201806710D0 (en) Capsule
CL2017001147S1 (es) Cápsula
CL2017001140S1 (es) Cápsula
CL2017001146S1 (es) Cápsula
CL2017001144S1 (es) Cápsula
CL2017001143S1 (es) Cápsula
CL2017001142S1 (es) Cápsula
CL2017001145S1 (es) Cápsula